Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-466-3500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.64 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Keryx Biopharmaceuticals (NASDAQ:KERX) Frequently Asked Questions
What is Keryx Biopharmaceuticals' stock symbol?
Keryx Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KERX."
How were Keryx Biopharmaceuticals' earnings last quarter?
Keryx Biopharmaceuticals (NASDAQ:KERX) posted its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The biopharmaceutical company had revenue of $28.04 million for the quarter, compared to analyst estimates of $29.56 million. View Keryx Biopharmaceuticals' Earnings History.
What price target have analysts set for KERX?
5 Wall Street analysts have issued 12 month price objectives for Keryx Biopharmaceuticals' stock. Their forecasts range from $4.00 to $9.00. On average, they expect Keryx Biopharmaceuticals' share price to reach $6.75 in the next year. View Analyst Price Targets for Keryx Biopharmaceuticals.
What is the consensus analysts' recommendation for Keryx Biopharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Keryx Biopharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Keryx Biopharmaceuticals.
What are Wall Street analysts saying about Keryx Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Keryx Biopharmaceuticals stock:
- 1. HC Wainwright analysts commented, "Valuation compelling. Keryx stock price has pulled back since the merger was announced in June, losing 33% of its value versus the XBI Biotech index losing only 9%. However we see only improving fundamentals as Auryxia revenues continue to improve QoQ." (11/9/2018)
- 2. Maxim Group analysts commented, "Keryx reported 3Q18 with total revenue of $28.0M, a slight miss from the consensus estimate of $29.1M. US Auryxia sales for the quarter were $26.6M up 11% q/q, driven by increased RX volume. The company reported a net loss of ($17.0M) and ended the quarter with $41.1M in cash." (11/9/2018)
- 3. According to Zacks Investment Research, "Keryx is completely dependent on Auryxia for growth as it is the only approved product in the company’s portfolio. Auryxia faces stiff competition in the United States from existing players. Shares of the company have underperformed the industry so far this year. However, Keryx's launch of Auryxia for the second indication — iron deficiency anemia (IDA) in chronic kidney disease patients — is boosting sales of the company, given that the IDA market holds great potential. Keryx entered a definitive merger agreement with Akebia Therapeutics that will create a fully integrated company focused on the development and commercialization of therapeutics for patients with chronic kidney diseases. The combined company will be well positioned to create significant shareholder value and accelerate growth beyond what either company would achieve separately. Loss estimates have remained stable ahead of Q3 earnings release." (10/9/2018)
Has Keryx Biopharmaceuticals been receiving favorable news coverage?
Media coverage about KERX stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Keryx Biopharmaceuticals earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Keryx Biopharmaceuticals' key competitors?
Some companies that are related to Keryx Biopharmaceuticals include Aimmune Therapeutics (AIMT), Clovis Oncology (CLVS), Theravance Biopharma (TBPH), Cambrex (CBM), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Epizyme (EPZM), Rhythm Pharmaceuticals (RYTM), CannTrust (CNTTF), Ra Pharmaceuticals (RARX) and Inflarx (IFRX).
What other stocks do shareholders of Keryx Biopharmaceuticals own?
Who are Keryx Biopharmaceuticals' key executives?
Keryx Biopharmaceuticals' management team includes the folowing people:
- Ms. Jodie Pope Morrison, Interim CEO & Director (Age 43)
- Mr. Scott A. Holmes, CFO, Sr. VP & Treasurer (Age 44)
- Ms. Christine A. Carberry, Sr. VP & COO (Age 57)
- Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 65)
- Mr. Tony Chambers, VP of Sales
How do I buy shares of Keryx Biopharmaceuticals?
Shares of KERX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How big of a company is Keryx Biopharmaceuticals?
Keryx Biopharmaceuticals has a market capitalization of $0.00 and generates $60.64 million in revenue each year. The biopharmaceutical company earns $-163,440,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.
What is Keryx Biopharmaceuticals' official website?
How can I contact Keryx Biopharmaceuticals?
Keryx Biopharmaceuticals' mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 617-466-3500 or via email at [email protected]
MarketBeat Community Rating for Keryx Biopharmaceuticals (NASDAQ KERX)
MarketBeat's community ratings are surveys of what our community members think about Keryx Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KERX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KERX will underperform the S&P 500 over the long term. You may vote once every thirty days.
